Optimi Health to Supply MDMA to MAPS Israel's Clinical Trial for Trauma-Related PTSD Psychedelics Investing
Compass Pathways Announces Third Quarter 2025 Financial Results and Business Highlights Including Acceleration of Commercial Launch Plans by 9-12 Months Psychedelics Investing
NeuroKaire Enters into R&D Collaboration with Compass Pathways to Pioneer Precision Treatments for Depression Psychedelics Investing
Right Season Investments Engages MCS Market Communication Service to Provide Market Support Psychedelics Investing
Compass Pathways to Announce Third Quarter Financial Results on November 4, 2025 Psychedelics Investing
